AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

SKYRIZI is the new option for psoriatic arthritis.

Drug Development

AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff

Humira will begin to lose exclusivity in 2023, and numerous biosimilar competitors are waiting to break in on the drug’s lucrative market.

February 2, 2022

4 min read

Mark Terry

Drug Development

AbbVie’s SKYRIZI Offers New Option for Psoriatic Arthritis Sufferers

The U.S. Food and Drug Administration has approved SKYRIZI (risankizumab-rzaa), AbbVie’s proposed treatment for adults diagnosed with active psoriatic arthritis (PsA).

January 24, 2022

2 min read

Vanessa Doctor, RN

Policy

Impostors! Crime in the Time of COVID-19 Targets Life Science Industry

While many of these scams targeted the public at large, scammers also turned their sights to those sources that would naturally be on the spot as the result of demand.

January 17, 2022

5 min read

Kaylei Whalen

Bio NC

BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

January 17, 2022

6 min read

Heather McKenzie

Courtesy of Smith Collection/Gado/Getty Images

Drug Development

AbbVie’s Rinvoq Racks Up Expanded Win In Atopic Dermatitis

Expanded approval for Rinvoq was based on three Phase III studies that included more than 2,500 patients. The studies met all primary and secondary endpoints.

January 17, 2022

2 min read

Alex Keown

Drug Development

JPM Day 3: AbbVie Sees Bright Future Ahead, vTv, Gritstone and Achilles

Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.

January 13, 2022

4 min read

Alex Keown

Business

ONK Snags $21.5 Million for Natural Killer Cell Therapies

ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.

January 6, 2022

2 min read

Kate Goodwin

Biotech Bay

Predicting the Life Sciences Investment Market in 2022

Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.

January 5, 2022

5 min read

Heather McKenzie

Courtesy Niels Wenstedt/BSR Agency via Getty Image

Business

Janssen Cuts Ties with Theravance After IBD Program Flop

Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.

December 23, 2021

2 min read

Kate Goodwin

JOBS